Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Creatine (Cr) and cyclocreatine (cyCr) have been shown to inhibit the growth of a variety of human and murine tumours. The purpose of this study was to evaluate the anti-tumour effect of these molecules in relation to drug accumulation, energy metabolism, tumour water accumulation and toxicity. Nude mice carrying a human colon adenocarcinoma (LS174T) with a creatine kinase (CK) activity of 2.12 units mg(-1) protein were fed Cr (2.5% or 5%) or cyCr (0.025%, 0.1% or 0.5%) for 2 weeks and compared with controls fed standard diet. Cr concentrations of 2.5% and 5% significantly inhibited tumour growth, as did 0.1% and 0.5% cyCr. In vivo 31P magnetic resonance spectroscopy (MRS) after 2 weeks of treatment showed an increase in [phosphocreatine (PCr)+phosphocyclocreatine (PcyCr)]/nucleoside triphosphate (NTP) with increasing concentrations of dietary Cr and cyCr, without changes in absolute NTP contents. The antiproliferative effect of the substrates of CK was not related to energy deficiency but was associated with acidosis. Intratumoral substrate concentrations (measured by 1H-MRS) of 4.8 micromol g(-1) wet weight Cr (mice fed 2.5% Cr) and 6.2 micromol g(-1) cyCr (mice fed 0.1% cyCr) induced a similar decrease in growth rate, indicating that both substrates were equally potent in tumour growth inhibition. The best correlant of growth inhibition was the total Cr or (cyCr+Cr) concentrations in the tissue. In vivo, these agents did not induce excessive water accumulation and had no systemic effects on the mice (weight loss, hypoglycaemia) that may have caused growth inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011
Inhibition of rate of tumor growth by creatine and cyclocreatine
Miller, E. E., Evans, A. E., & Cohn, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3304 · Cited by 82 · cited 2×
“…d K ere e re ore d e t dose ri. d of nl, ve er r - effect was achieved at an oral dose of cyCr 5–10 times lower in the studies by Lillie et al (1993) and Miller et al (1993), wher the effective i.p. dose in this study (10 mg daily) was comparab the i.p. dose used by others (Teicher et al, 1995;…”
Background
Cited by
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
Mitochondrial creatine kinase in human health and disease
Schlattner, U., Tokarska-Schlattner, M., & Wallimann, T. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.09.004 · Cited by 622
Wu, G. (2020) · Amino Acids · doi:10.1007/s00726-020-02823-6 · Cited by 475
Creatine metabolism: energy homeostasis, immunity and cancer biology
Kazak, L., & Cohen, P. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0365-5 · Cited by 265
Creatine uptake regulates CD8 T cell antitumor immunity
Di Biase, S., Ma, X., Wang, X., Yu, J., Wang, Y.-C., Smith, D. J., Zhou, Y., Li, Z., Kim, Y. J., Clarke, N., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182044 · Cited by 132
Metadata
- Authors
- Kristensen, C. A., Askenasy, N., Jain, R. K., & Koretsky, A. P.
- Venue
- British Journal of Cancer
- Published
- 1998-12-18
- Volume
- 79
- Issue
- 2
- Pages
- 278-285
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1968257470
- Cited by
- 54
- References
- 2
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.